1294 related articles for article (PubMed ID: 34867978)
1. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
2. Covid-19 and development of heart failure: mystery and truth.
Onohuean H; Al-Kuraishy HM; Al-Gareeb AI; Qusti S; Alshammari EM; Batiha GE
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2013-2021. PubMed ID: 34480616
[TBL] [Abstract][Full Text] [Related]
3. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
4. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
[TBL] [Abstract][Full Text] [Related]
5. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
[TBL] [Abstract][Full Text] [Related]
6. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
8. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.
Al-Kuraishy HM; Al-Gareeb AI; Negm WA; Alexiou A; Batiha GE
Inflammopharmacology; 2022 Oct; 30(5):1493-1501. PubMed ID: 35922738
[TBL] [Abstract][Full Text] [Related]
9. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P
Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680
[TBL] [Abstract][Full Text] [Related]
11. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.
Nadwa EH; Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Albogami SM; Alorabi M; Batiha GE; De Waard M
Naunyn Schmiedebergs Arch Pharmacol; 2023 Mar; 396(3):453-468. PubMed ID: 36460816
[TBL] [Abstract][Full Text] [Related]
13. Management of hyperinflammation in COVID-19 patients.
Suberviola B; Cuenca Fito E
Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):6-9. PubMed ID: 36285849
[TBL] [Abstract][Full Text] [Related]
14. Nitazoxanide and COVID-19: A review.
Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Batiha GE
Mol Biol Rep; 2022 Nov; 49(11):11169-11176. PubMed ID: 36094778
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
17. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
18. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
20. How could perfluorocarbon affect cytokine storm and angiogenesis in coronavirus disease 2019 (COVID-19): role of hypoxia-inducible factor 1α.
Moasefi N; Fouladi M; Norooznezhad AH; Yarani R; Rahmani A; Mansouri K
Inflamm Res; 2021 Jul; 70(7):749-752. PubMed ID: 34173853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
